QIAGEN N.V.

QGEN Healthcare Diagnostics & Research

QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 7.94%, free cash flow grew 30.5% and total debt rose 13.8%, each against the same quarter a year earlier.

46.13 0.04 −0.09%
Market cap
$9.5B
P/E
23.6×
Fwd P/E
17.5×
Dividend yield
0.76%
F-score
8/9
Altman Z
3.81
Beneish M
−2.60
Dividend safety
66/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
20.03 20.91 22.30 23.07

+8 more quarters

P/S ratio
3.84 3.95 4.67 4.45
P/FCF ratio
18.31 20.52 21.84 19.48
P/Operating CF
40.20 82.37 51.92 55.78
P/B ratio
2.40 2.49 2.59 2.52
Price to Tangible BV
25.86 30.90 14.14 11.54
EV/Sales
4.25 4.66 5.18 4.66
EV/EBITDA
13.70 15.31 16.33 14.16
EV/Operating CF
13.63 15.91 16.54 14.66
EV/FCF
20.24 24.24 24.20 20.41
Quick Ratio
2.04 2.18 2.93 2.12
Current Ratio
2.85 3.21 3.90 2.60
Net Debt/EBITDA
4.63 7.34 3.71 2.41
Debt/Assets
27.91% 28.48% 26.34% 32.46%
Debt/Equity
0.49 0.49 0.44 0.58
Asset Turnover
0.36 0.37 0.35 0.32
Operating CF/Net income
1.94 1.48 1.74 1.27
Capex/Depreciation
(0.85) (0.94) (1.42) (0.97)
Interest Coverage
13.21 7.64 9.81 15.72
Research and Development Expense of Revenue
9.43% 9.80% 8.74% 9.15%
Selling, General and Administrative Expense of Revenue
27.43% 28.92% 28.47% 26.87%
Intangible Assets out of Total Assets
0.52 0.53 0.49 0.44
Share Based Compensation of Revenue
1.30% 1.96% 3.07% 2.01%
Graham Net Nets
(0.11) (0.11) (0.05) (0.04)
Graham Number
26.73 26.33 28.09 27.78
Earnings Yield
4.99% 4.78% 4.48% 4.34%
Free Cash Flow Yield
5.46% 4.87% 4.58% 5.13%
Revenue per Share
2.59 2.38 2.49 2.59
Operating CF per Share
0.97 0.49 0.87 0.80
Capex per Share
(0.21) (0.23) (0.33) (0.24)
Free Cash Flow per Share
0.76 0.25 0.54 0.56
Cash per Share
3.85 3.12 5.06 8.20
Shareholders Equity per Share
16.27 16.09 17.39 17.71
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
16.27 16.09 17.39 17.71
Free Cash Flow
157.32 52.15 116.55 114.57
Working Capital
1,075.18 1,061.14 1,482.94 1,557.53
Capital Expenditures
(43.37) (48.48) (71.58) (50.45)
Net Current Asset Value
(874.83) (910.10) (508.00) (373.14)
EV/EBIT
20.02 22.51 23.23 19.86
Capex to Sales
0.08 0.10 0.13 0.09
Price to Operating Income
18.11 19.06 20.97 18.96
Other line items
Average Receivables
387.80 368.66 375.94 360.57
Average Payables
80.71 73.98 77.96 76.89
Average Inventory
301.95 295.49 290.57 305.96
Average Assets
5,856.48 5,663.72 5,985.43 6,411.85
Average Common Equity
3,431.62 3,369.79 3,672.75 3,589.70

Fold the line items

Columns are period end dates